

## AMCP Corporate Member Spotlight: Sage Therapeutics



AMCP News&Views caught up recently with Todd Grisco, Vice President for Market Access at Sage Therapeutics to get his thoughts on becoming a Corporate Member, as well as how Sage is poised to make an impact for patients in the months ahead:

**N&V: As you considered becoming a Corporate Member, what tipped the scales?**

*As a clinical-stage company that is on a mission to develop and commercialize novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders, Sage is excited to engage with a variety of stakeholders to advance that objective. Now, as a member company with AMCP, we have the opportunity to both broaden and deepen this engagement with the Academy's 8,000 pharmacists, physicians, nurses and other practitioners—as well as with other member companies and organizations. “Doing Big” is one of our core values at Sage, and this requires us to set our sights high, and collaborate and foster innovation in its many varieties from R&D to Commercialization. Our involvement with AMCP will no doubt help to support these efforts and challenge us in our mission to help make life better for patients with CNS diseases by discovering, developing, and delivering important new medicines for patients in need.*

**N&V: What is your strategy and anticipated innovations for 2018?**

*Sage investigates modulation of GABA and NMDA receptors—two critical neurotransmitter systems. Dysfunction in these systems is known to be at the core of numerous psychiatric and neurological disorders and our novel compounds are intended to alter activity at these receptors by working with the brain's endogenous signaling mechanisms. We believe compounds that help to restore balance between excitatory and inhibitory signals within the brain have the potential to treat a range of CNS disorders associated with a variety of cognitive, neurological, and behavioral symptoms. In 2018, we expect to advance multiple products from our fully-owned portfolio in clinical trials. And as to our most advanced product candidate (brexanolone IV), we are preparing for a planned NDA submission.*

**N&V: What's your one-minute elevator speech about your company?**

*Sage is thinking differently about data with a practical and deliberate approach to drug development and a focus on treatments for people whose disorders need more treatment options. We explore innovative methods of drug discovery and development, as well as clinical trial design, in pursuit of novel treatments for central nervous system disorders that may address gaps in the efficacy and safety profile of current therapies. It's an exciting time in neuroscience, and we are passionate about developing novel medicines to treat life-altering CNS disorders. Our focused, practical and deliberate approach is designed to facilitate rapid advancement of potential treatments from discovery through clinical development.*